Regulatory Strategy Services

Strategic regulatory planning and guidance for global drug development programs

Strategic Regulatory Guidance

SXR Laboratories provides comprehensive regulatory strategy services to optimize development pathways and accelerate time to market. Our regulatory experts navigate complex requirements across global jurisdictions, securing regulatory designations and facilitating productive agency interactions.

Strategic Planning Services

Development pathway optimization and milestone planning
Target Product Profile (TPP) development and refinement
Regulatory risk assessment and mitigation strategies
Global regulatory strategy harmonization
Pediatric Investigation Plan (PIP) and Pediatric Study Plan (PSP)
Post-approval commitment strategy

Special Designations & Pathways

FDA: Fast Track, Breakthrough Therapy, Priority Review, Accelerated Approval
EMA: PRIME, Conditional Approval, Accelerated Assessment
Orphan Drug Designation: FDA, EMA, and PMDA applications
RMAT: Regenerative Medicine Advanced Therapy designation
Rare Pediatric Disease designation and priority review vouchers
Rolling review and pre-submission strategies

Agency Interactions

We prepare and lead critical regulatory meetings including Pre-IND, End-of-Phase 2, Pre-NDA/BLA meetings with FDA, and Scientific Advice procedures with EMA. Our services include briefing document preparation, meeting strategy, response to agency questions, and meeting minutes with actionable recommendations. We maintain productive relationships with health authorities worldwide to facilitate development programs.